New Emerging Targets in Cancer Immunotherapy: the Role of TIM3

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2019 Jul 6

PMID 31275616

Citations 52

Authors

Alex Friedlaender

Alfredo Addeo

Giuseppe Banna

Affiliations

Soon will be listed here.

Abstract

Currently, the programmed death-1/programmed death ligand-1 and the cytotoxic T-lymphocyte-associated protein 4 are the two commonly targeted immune-checkpoint inhibition pathways. These drugs have significantly improved the prognosis of many cancer types. While immune-checkpoint inhibitors have revolutionised the treatment of many cancer types, the majority of patients still progress. Several treatment strategies have been pursued to improve current results. One approach is to combine two checkpoint inhibitors, currently with promising results in melanoma, renal cell carcinoma and a subset of non-small-cell lung cancer patients. The identification of new checkpoint targets could allow the field of immuno-oncology to evolve further. We will discuss one of the most promising immune-checkpoint targets currently under investigation, the T-cell immunoglobulin and mucin domain-3.

Citing Articles

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back.

Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A BioDrugs. 2025; 39(2):215-235.

PMID: 39954220 PMC: 11906525. DOI: 10.1007/s40259-024-00700-2.

Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression.

Luo J, Zhang C, Chen D, Chang T, Chen S, Lin Z Eur J Med Res. 2024; 29(1):583.

PMID: 39696711 PMC: 11656820. DOI: 10.1186/s40001-024-02203-w.

Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.

Franzese O Int J Mol Sci. 2024; 25(23).

PMID: 39684559 PMC: 11641238. DOI: 10.3390/ijms252312848.

Potential of natural products and gut microbiome in tumor immunotherapy.

Cao L, Wang X, Ma X, Xu M, Li J Chin Med. 2024; 19(1):161.

PMID: 39567970 PMC: 11580227. DOI: 10.1186/s13020-024-01032-7.

CircPVT1 promotes migration and invasion by regulating miR-490-5p/HAVCR2 axis in osteosarcoma cells.

Zhou C, Balmer L, Song M, Wu K, Wang W, Wang H J Cell Mol Med. 2024; 28(8):e18269.

PMID: 38568056 PMC: 10989635. DOI: 10.1111/jcmm.18269.

References

Monney L, Sabatos C, Gaglia J, Ryu A, Waldner H, Chernova T . Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415(6871):536-41. DOI: 10.1038/415536a. View

Sabatos C, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng X . Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003; 4(11):1102-10. DOI: 10.1038/ni988. View

Swann J, Smyth M . Immune surveillance of tumors. J Clin Invest. 2007; 117(5):1137-46. PMC: 1857231. DOI: 10.1172/JCI31405. View

Jones R, Ndhlovu L, Barbour J, Sheth P, Jha A, Long B . Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008; 205(12):2763-79. PMC: 2585847. DOI: 10.1084/jem.20081398. View

Sakuishi K, Apetoh L, Sullivan J, Blazar B, Kuchroo V, Anderson A . Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207(10):2187-94. PMC: 2947065. DOI: 10.1084/jem.20100643. View

Ngiow S, Von Scheidt B, Akiba H, Yagita H, Teng M, Smyth M . Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011; 71(10):3540-51. DOI: 10.1158/0008-5472.CAN-11-0096. View

Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M . Maintenance therapy in NSCLC: why? To whom? Which agent?. J Exp Clin Cancer Res. 2011; 30:50. PMC: 3113744. DOI: 10.1186/1756-9966-30-50. View

Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F . TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012; 7(2):e30676. PMC: 3281852. DOI: 10.1371/journal.pone.0030676. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

10.

Spiess C, Zhai Q, Carter P . Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015; 67(2 Pt A):95-106. DOI: 10.1016/j.molimm.2015.01.003. View

11.

Kontermann R, Brinkmann U . Bispecific antibodies. Drug Discov Today. 2015; 20(7):838-47. DOI: 10.1016/j.drudis.2015.02.008. View

12.

Koyama S, Akbay E, Li Y, Herter-Sprie G, Buczkowski K, Richards W . Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016; 7:10501. PMC: 4757784. DOI: 10.1038/ncomms10501. View

13.

Yu S, Li A, Liu Q, Yuan X, Xu H, Jiao D . Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol. 2017; 10(1):155. PMC: 5607507. DOI: 10.1186/s13045-017-0522-z. View

14.

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

15.

Hellmann M, Ciuleanu T, Pluzanski A, Lee J, Otterson G, Audigier-Valette C . Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22):2093-2104. PMC: 7193684. DOI: 10.1056/NEJMoa1801946. View

16.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

17.

Chae Y, Arya A, Iams W, Cruz M, Chandra S, Choi J . Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018; 6(1):39. PMC: 5956851. DOI: 10.1186/s40425-018-0349-3. View

18.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

19.

Dahlen E, Veitonmaki N, Norlen P . Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. 2018; 6(1):3-17. PMC: 5933537. DOI: 10.1177/2515135518763280. View

20.

Banna G, Passiglia F, Colonese F, Canova S, Menis J, Addeo A . Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol. 2018; 129:27-39. DOI: 10.1016/j.critrevonc.2018.06.016. View